Skip to main content

Market Overview

Recap: Intra-Cellular Therapies Q2 Earnings

Share:

Shares of Intra-Cellular Therapies (NASDAQ:ITCI) fell 2% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share decreased 41.18% year over year to ($0.96), which missed the estimate of ($0.91).

Revenue of $1,907,000 higher by 0.00% from the same period last year, which missed the estimate of $3,030,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Aug 10, 2020

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/wen7vxux

Recent Stock Performance

52-week high: $43.56

52-week low: $6.75

Price action over last quarter: Up 7.13%

Company Overview

Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

 

Related Articles (ITCI)

View Comments and Join the Discussion!

Posted-In: Earnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com